期刊文献+

缬沙坦氨氯地平(倍博特)治疗老年蛋白尿临床疗效观察 被引量:2

Observation on the clinical curative effect of valsartan amlodipine (Bebot) in the treatment of senile proteinuria
下载PDF
导出
摘要 目的研究缬沙坦氨氯地平(倍博特)治疗老年蛋白尿的临床疗效。方法选取我院120例老年蛋白尿异常患者为研究对象,抽签随机分为A、B、C三组,三组均为40例,A组采取氨氯地平片治疗,5mg/d;B组给予缬沙坦80mg/d;C组给予缬沙坦氨氯地平(80mg:5mg)/d;三组均治疗6个月,于治疗前、治疗3月及治疗6月后观察两组血压指标变化及治疗前后尿蛋白水平差异。结果用药前三组SBP及DBP比较差异无统计学意义(P〉0.05),治疗3月后三组SBP及DBP与治疗前比较均降低,C组SBP、DBP显著低于A、B组,治疗6月后C组血压指标显著低于A、B组,而A、B组比较差异无统计学意义(P〉0.05);B、C三组治疗前Pro、BUN、SCr比较差异无统计学意义(P〉0.05),治疗后三组Pro、BUN、SCr均降低,且C组治疗后Pro、BUN、SCr均显著低于A、B组,差异有统计学意义(P〈0.05)。结论缬沙坦氨氯地平治疗老年蛋白尿较单一应用缬沙坦或氨氯地平疗效更为显著,可改善尿蛋白水平、血压等指标,具有较高的临床应用价值。 Objective To study the curative effect of valsartan amlodipine (Bebot) in the treatment of senile proteinuria. Methods 120 elderly patients with proteinuria in our hospital were selected as the research object, and randomly divided into group A, B, C by drawing lots with 40 cases in each group. Group A was treated by amlodipine tablet, 5 mg/d, group B was treated by valsartan, 80 mg/d, and group C was treated by valsartan amlodipine, (80 mg : 5 mg)/d. Three groups were treated for 6 months. Before the treatment, 3 months and 6 months of treatment later, the changes of blood pressure indexes and the differences in urine protein levels in three groups were observed. Results Before drug use, there were no statistically significant differences in SBP and DBP between three groups (P〉0.05). 3 months of treatment later, SBP and DBP in three groups were lower than those before the treatment. SBP and DBP in group C were significantly lower than those in group A and B. 6 months of treatment later, blood pressure indexes in group C were significantly lower than those in group A and B, but there were no statistically significant differences between group A and B (P〉0.05). Before the treatment, there were no statistically significant differences in Pro, BUN and SCr between three groups (P〉0.05). After treatment, Pro, BUN and SCr in three groups all decreased, and Pro, BUN and SCr after treatment in group C were significantly lower than those in group A and B (P〈0.05). Conclusion The curative effect of valsartan amlodipine in the treatment of elderly patients with proteinuria is more significant than single application of valsartan or amlodipine. It can improve the urinary protein level, blood pressure and other indicators, of high clinical application value.
出处 《国际医药卫生导报》 2016年第1期83-85,共3页 International Medicine and Health Guidance News
关键词 缬沙坦 氨氯地平 老年蛋白尿 Valsartan Amlodipine Senile proteinuria
  • 相关文献

二级参考文献77

  • 1单文卫,申丽萍,常晓红.沙坦类降压药的研究现状与临床评价[J].中国心血管病研究,2009,7(8):622-625. 被引量:14
  • 2罗冬青.用缬沙坦联合左旋氨氯地平治疗糖尿病肾病合并高血压的疗效观察[J].求医问药(下半月),2013(7):82-84. 被引量:6
  • 3周齐娜,付青梅,李源.老年糖尿病合并高血压的临床治疗[J].国外医学(老年医学分册),2007,28(3):114-118. 被引量:8
  • 4Matsuzaki G,Ishizaka N,Furuta K,et al.Comparison of vasculo-protective effects of benidipine and losartan in a rat model of meta-bolic syndrome[J].Eur J Pharmacol,2008,587(1-3):237-242.
  • 5Takayama M,Arakawa E,Yao K,et al.Effects of combination ofangiotensin receptor blocker and calcium channel blocker on ox-LDLlevels and cardiovascular dysfunction in Dahl rats[J].Pharmacolo-gy,2006,77(4):179-187.
  • 6Croom KF,Curran MP,Goa KL,et al.Irbesartan:a review of itsuse in hypertension and in the management of diabetic nephropathy[J].Drugs,2004,64(9):999-1028.
  • 7Rahman M,Brown CD,Coresh J,et al.The prevalence of reducedglomerular filtration rate in older hypertensive patients and its associ-ation with cardiovascular disease:a report from the Antihypertensiveand Lipid-Lowering Treatment to Prevent Heart Attack Trial[J].Arch Intern Med,2004,164(9):969-976.
  • 8Nathan S,Pepine CJ,Bakris GL.Calcium antagonists:effects oncardio-renal risk in hypertensive patients[J].Hypertension,2005,46(4):637-642.
  • 9Taddei S,Virdis A,Ghiadoni L,et al.Calcium antagonist treat-ment by lercanidipine prevents hyperpolarization inessential hyper-tension[J].Hypertension,2003,41(4):950-955.
  • 10Gashti CN,Bakris GL.The role of calcium antagonists in chronickidney disease[J].Curr Opin Nephrol Hypertens,2004,13(2):155-161.

共引文献77

同被引文献19

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部